Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
October 24, 2011
RegMed Daily, Mid-Day, 10/24/11, defining the next 2 months' market, stocks flat line to slow recovery
October 20, 2011
RegMed Daily, Mid-Day, 10/20/11, headline risks weigh the range bound market
October 18, 2011
RegMed Daily, Mid-Day, 10/18/11, defining expectation, call me tomorrow, then the next day and so forth
October 14, 2011
RegMed Daily, Mid-Day, 10/14/11, perception is reality in this market
October 11, 2011
RegMed Daily, Mid-Day, 10/11/11, markets are nervous and threaten by minny mouse countries
October 11, 2011
ThermoGenesis (KOOL) acceptance of AXP® Submission by Regulatory Body in China
October 10, 2011
RegMed Daily, Mid-Day, 10/10/11, no risk-on or risk-off, just a good old rally
October 7, 2011
RegMed Daily, Mid-Day, 10/7/11, a multiple data and non-committal day
October 6, 2011
RegMed Daily, Mid-Day, 10/6/11, overshadowed by Icon Steve Jobs death, EU fiascoes and coming unemployment numbers
October 5, 2011
RegMed Daily, Mid-Day, 10/5/11, universe is fading, pausing on the way down
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.